

Newbury Pharmaceuticals appoints Lars Minor as the new CEO

Lars Minor assumes the new role from September 1, 2021 and will be stationed at Newbury's office at Medicon Village in Lund. He will be responsible for the company's overall strategy and provide the necessary direction, business development and commercial operation. Karl Karlsson will continue fulltime as Newbury's Executive Chairman.

"We are delighted to onboard Lars as the new CEO while we target significant growth the coming years and establish ourselves as a local champion for specialty prescription drugs in Scandinavia. Lars' strong background in commercial leadership roles makes him well suited to, together with the leadership team, build Newbury into a successful company" says Karl Karlsson, Founder & Executive Chairman.

Lars' previous position was Corporate Vice President for strategy and execution at LEO Pharma, responsible for leading the global strategy. Prior to that position Lars has had P&L responsibility for emerging markets and Europe at LEO Pharma. He has notable experience in negotiations, business development and alliance management combined with extensive experience from scaling businesses for growth and regional market experience in Europe. Lars combines strong pharmaceutical and operational expertise with strategic and commercial thinking.

"Newbury Pharmaceuticals' hybrid business model with a combination of innovative products, orphan drugs and niche generics, as well as branded and value-added formulations, is very exciting. I look forward to grow the business and evolve the portfolio the next coming years" says Lars Minor.

For more information contact:

Karl Karlsson, Founder, Executive Chairman

karl.karlsson@newburypharma.com

Mobil: +46-46-121 120

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury Pharmaceuticals wants to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging its experience and extensive international network whereby Newbury can offer strategic partnerships of innovation for the benefit of the Nordic healthcare market.